跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

Abbott GmbH

首页临床试验发起方与机构Abbott GmbH

Abbott GmbH

Max-Planck-Ring 2, Wiesbaden, Hessen, 德国

别名:

abbott gmbh & co. kg

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

287

285 进行中

药物批准

1

批准总数

监管机构

1

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

56

19.5%

试验状态分布

进行中（未招募）

285

99.3%

已完成

2

0.7%

相关临床试验

该机构主办的试验（287）

ong term observational study on efficiency of a TNF-alpha blocker therapy on nail psoriasis in patients with moderate to severe plaque psoriasis or psoriatic arthritis

Jun 2019755 名受试者

A randomized, open-label study to evaluate the safety and Effect of three experimental drugs ABT-450, ABT-267 and ABT-333 Coadministered with Ribavirin (RBV) in people with Genotype 1 hepatitis C Virus (HCV) and early liver damage. Experimental means that they have not been approved by any regulatory agency for sale to the public.

进行中（未招募）

Jun 2013381 名受试者

A Multi-Center, Open-Label Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects with Moderate to Severe Crohn's Disease.Estudio multicéntrico abierto, del anticuerpo monoclonal humano anti-TNF Adalimumab, en inducción y mantenimiento de la remisión clínica en sujetos con Enfermedad de Crohn moderada a grave.

进行中（未招募）

Jun 20131000 名受试者

A study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 co-administered with Ribavirin (RBV) in people that have been previously treated for Hepatitis C Virus (HCV). Experimental means that they have not been approved by any regulatory agency for sale to the public.

进行中（未招募）

May 2013400 名受试者

A double-blind, placebo-controlled study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 with or without ribavirin in people with hepatitis C virus (HCV) that have not been treated before. Experimental means that they have not been approved by any regulatory agency for sale to the public.

进行中（未招募）

Mar 2013400 名受试者

A double-blind, placebo-contolled study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 coadministered with Ribavirin (RBV) in people with hepatitis C virus (HCV) that have not been treated before. Experimental means that they have not been approved by any regulatory agency for sale to the public.

进行中（未招募）

Mar 2013600 名受试者

A study to evaluate the safety and effect of three experimental drugs ABT-450, ABT-267, and ABT-333 co-administered with Ribavirin (RBV) in people that have been previously treated for Hepatitis C Virus (HCV). Experimental means that they have not been approved by any regulatory agency for sale to the public.

进行中（未招募）

Jan 2013400 名受试者

A randomized, open-label study to evaluate the safety and Effect of three experimental drugs ABT-450, ABT-267 and ABT-333 Coadministered with Ribavirin (RBV) in people with Genotype 1 hepatitis C Virus (HCV) and early liver damage. ''Experimental'' means that they have not been approved by any regulatory agency for sale to the public.

进行中（未招募）

Jan 2013381 名受试者

第 1 页，共 36 页

药物批准

按机构分类的批准

CIMA_AEMPS

Spanish Agency for Medicines and Medical Devices

1

药物批准

近期批准

MANIDON HTA COMPRIMIDOS DE LIBERACION GRADUAL

资讯

暂无资讯文章

本页目录

概览
相关临床试验287
药物批准1
资讯

返回机构列表